CMS issues final guidance on how to bill correctly with drug test G-codes

Why This Topic Matters

Correct drug testing billing affects Medicare claims accuracy, compliance, and whether services are reported under the appropriate updated code set and waiver status. The article helps readers understand the scope of CMS’s final guidance and the general categories of changes involved without replacing the full premium content.

Article Sections

1. Billing changes for Medicare drug screening

   Introduces the CMS update affecting drug screening claims and the broader transition in reporting for Medicare patients. The section frames the guidance in terms of billing changes and effective timing.

2. Temporary guidelines and final effective guidance

   Summarizes the earlier temporary reporting period and the later final CMS guidance. This section places the update in context for practices tracking implementation dates.

3. Appropriate code use by test type and lab status

   Outlines the general categories of reporting guidance tied to test methodology, number of drug classes, and CLIA-waived versus non-waived settings. The section helps readers identify the decision areas covered by the article.

4. Official CMS resources

   Lists the CMS references associated with the guidance, including transmittal and MLN material. This section points readers to the source documents cited in the article.